1 prior line of therapy, Cyclophosphamide+Velcade+Dexamethasone (CVd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Phase 2
### Instruction:
Identify the study with the following condition. 
### Input:
1 prior line of therapy, Cyclophosphamide+Velcade+Dexamethasone (CVd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Phase 2 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232